Adial Pharmaceuticals (ADIL) Profit After Tax (2017 - 2026)

Adial Pharmaceuticals has reported Profit After Tax for 10 years, with the latest figure at -$2.0 million in Q1 2026.

• Quarterly Profit After Tax rose 13.49% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.4 million (up 23.04% YoY) and the FY2025 annual result came in at -$8.0 million, up 39.56% from the prior year.
• Profit After Tax climbed to -$2.0 million in Q1 2026 per ADIL's latest filing, from -$6.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $1.1 million in Q2 2023 and troughed at -$11.1 million in Q3 2024.
• A 5-year average of -$3.1 million and a median of -$2.7 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax jumped 128.27% in 2023, then plunged 703.38% in 2024.
• Over 5 years, Profit After Tax stood at -$931416.0 in 2022, then decreased by 4.61% to -$974373.0 in 2023, then slumped by 48.13% to -$1.4 million in 2024, then plunged by 314.4% to -$6.0 million in 2025, then jumped by 66.19% to -$2.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.0 million, -$6.0 million, and -$3.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.